Condensed Consolidated Statements of Cash Flows - USD ($)	9 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Cash flows from operating activities:
Net loss	$ (457,870,000)	$ (247,558,000)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	19,171,000	24,918,000
Amortization and impairment of internal-use software	4,374,000	3,214,000
Stock-based compensation expense	101,198,000	93,768,000
(Gain) loss on disposal of property and equipment	(5,000)	0
Loss on disposition of Lemonaid Health Limited	2,026,000	0
Impairment of long-lived assets	0	10,126,000
Goodwill impairment	198,800,000	0
Other operating activities	(504,000)	(1,000)
Changes in operating assets and liabilities:
Accounts receivable, net (includes related party amounts of $19 and $(3,636) for the nine months ended December 31, 2023 and 2022, respectively)	(16,257,000)	(23,428,000)
Inventories	(5,420,000)	(1,172,000)
Deferred cost of revenue	(6,846,000)	(6,636,000)
Prepaid expenses and other current assets	(4,490,000)	3,772,000
Operating lease right-of-use assets	5,341,000	5,570,000
Other assets	755,000	(711,000)
Accounts payable (includes related party amounts of $3,879 and $(12,567) for the nine months ended December 31, 2023 and 2022, respectively)	669,000	(23,305,000)
Accrued expenses and other current liabilities (includes related party amounts of $42 and $4,090 for the nine months ended December 31, 2023 and 2022, respectively)	(5,906,000)	4,265,000
Deferred revenue (includes related party amounts of $8,247 and $13,762 for the nine months ended December 31, 2023 and 2022, respectively)	32,948,000	45,996,000
Operating lease liabilities	(6,483,000)	(6,708,000)
Other liabilities	(36,000)	(2,539,000)
Net cash used in operating activities	(138,535,000)	(120,429,000)
Cash flows from investing activities:
Purchases of property and equipment	(850,000)	(2,854,000)
Proceeds from sale of property and equipment	6,000	0
Capitalized internal-use software costs	(6,636,000)	(5,163,000)
Net cash used in investing activities	(7,480,000)	(8,017,000)
Cash flows from financing activities:
Proceeds from exercise of stock options	687,000	3,933,000
Proceeds from issuance of common stock under employee stock purchase plan	1,411,000	3,238,000
Payments of deferred offering costs	(356,000)	0
Payments for taxes related to net share settlement of equity awards	(158,000)	0
Net cash provided by financing activities	1,584,000	7,171,000
Effect of exchange rates on cash and cash equivalents	0	694,000
Net decrease in cash, cash equivalents and restricted cash	(144,431,000)	(120,581,000)
Cash, cash equivalents and restricted cash—beginning of period	395,222,000	561,755,000
Cash, cash equivalents and restricted cash—end of period	250,791,000	441,174,000
Supplemental disclosures of non-cash investing and financing activities:
Purchases of property and equipment included in accounts payable and accrued expenses	213,000	472,000
Stock-based compensation capitalized for internal-use software costs	2,927,000	2,239,000
Reconciliation of cash, cash equivalents, and restricted cash within the condensed consolidated balance sheets to the amounts shown in the condensed consolidated statements of cash flows above:
Cash and cash equivalents	242,418,000	432,801,000
Restricted cash, current	1,399,000	1,399,000
Restricted cash, noncurrent	6,974,000	6,974,000
Total cash and restricted cash	$ 250,791,000	$ 441,174,000